Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gadolinium chloride is a chemical compound consisting of gadolinium and chloride ions, typically encountered as GdCl3. It is not used as a contrast agent for human imaging, but primarily as a research tool in preclinical studies. Gadolinium chloride acts as a selective toxicant for Kupffer cells (resident liver macrophages), allowing researchers to transiently inhibit macrophage function in animal models. It is also described as an agonist of the calcium-sensing receptor (CaSR), inducing NLRP3 inflammasome activation in bone marrow-derived macrophages. Its mechanism of action involves both Kupffer cell inhibition and pro-inflammatory effects depending on the context. It is not used clinically due to toxicity of free gadolinium ions; instead, safer chelated gadolinium compounds are used for human imaging. Gadolinum chloride has been investigated for its potential to attenuate drug-induced hepatotoxicity in research settings by modulating inflammatory responses and liver regeneration[1][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gadolinium chloride.